Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024)

Rockwell Medical's Non-Current Deffered Revenue history spans 9 years, with the latest figure at $429000.0 for Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue fell 9.68% year-over-year to $429000.0; the TTM value through Dec 2024 reached $429000.0, down 9.68%, while the annual FY2024 figure was $429000.0, 9.68% down from the prior year.
  • Non-Current Deffered Revenue reached $429000.0 in Q4 2024 per RMTI's latest filing, down from $441000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $9.5 million in Q1 2020 to a low of $429000.0 in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $4.4 million, with a median of $4.8 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 89.33% in 2023, then dropped 9.45% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $8.0 million in 2020, then fell by 25.32% to $6.0 million in 2021, then plummeted by 56.57% to $2.6 million in 2022, then crashed by 81.73% to $475000.0 in 2023, then decreased by 9.68% to $429000.0 in 2024.
  • Per Business Quant, the three most recent readings for RMTI's Non-Current Deffered Revenue are $429000.0 (Q4 2024), $441000.0 (Q3 2024), and $452000.0 (Q2 2024).